News and Publications

  • Transthyretin Amyloidosis (ATTRv): Advancing Early Diagnosis Through Genetic Testing

    Publications , Diagnostics November 12, 2025

    Transthyretin amyloidosis (ATTRv) is a progressive, life-threatening, and often underdiagnosed disease caused by the deposition of toxic transthyretin (TTR) amyloid fibrils in multiple tissues and… Read more

  • Press Release. ARCHIMEDlife achieves ISO 27001 Certification for Information Security Management

    ARCHIMEDlife News September 3, 2025

    Vienna, Austria – [03.09.2025] — ARCHIMEDlife, international disease-focused Medical Laboratories* in Precision Medicine for Rare Disease and Specialty Diagnostics, is proud to announce that it has successfully… Read more

  • Update on screening cut-offs for Gaucher and Pompe diseases

    April 28, 2025

    Effective 1 May 2025, the cut-off values for enzymatic testing for Gaucher and Pompe diseases have changed.The new Glucocerebrosidase (Gaucher) cut-off is changed to >1.2 µmol/L/h (old… Read more

  • Award for Outstanding Achievements on Rare Diseases

    ARCHIMEDlife News , Diagnostics April 17, 2025
    We are very happy to share that our CEO, Dr. David C. Kasper, has been selected as the winner of the Award for Outstanding Achievements in… Read more
  • WORLDSymposium 2025 Poster Presentations – Updates on important diagnostic services

    ARCHIMEDlife News , Diagnostics February 21, 2025
    The WORLDSymposium for Lysosomal Storage Disorders convened in San Diego, CA, USA earlier this month. This important meeting brings together industry, physicians, advocate groups, and… Read more
  • Newborn Screening and Presymptomatic Treatment of Metachromatic Leukodystrophy

    Metachromatic leukodystrophy (MLD) is a lysosomal storage disorder characterized by progressive neurodegeneration due to a deficiency in the enzyme arylsulfatase-A (ARSA). This deficiency leads to… Read more